BIOCRYST PHARMACEUTICALS, INC. Additional Paid in Capital, Common Stock
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Additional Paid in Capital, Common Stock of $546.70 million as of 2015-03-31, per its 10-Q filed 2015-05-08.
Discontinued › Balance Sheet
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2015-05-08
- 2015-03-31: Additional Paid in Capital, Common Stock $546.70M.
- 2014-12-31: Additional Paid in Capital, Common Stock $542.94M.
- 2014-09-30: Additional Paid in Capital, Common Stock $538.96M.
- 2014-06-30: Additional Paid in Capital, Common Stock $536.86M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2015-03-31 | $546.70M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $542.94M 10-Q · filed 2015-05-08 |
| 2014-09-30 | $538.96M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $536.86M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $426.52M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $420.99M 10-K · filed 2015-03-02 |
| 2013-09-30 | $420.10M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $399.68M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $393.74M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $391.61M 10-K · filed 2014-03-10 |
| 2012-09-30 | $390.78M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $386.97M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $382.18M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $367.83M 10-K · filed 2013-03-11 |
| 2011-09-30 | $365.87M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $364.59M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $361.52M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |